NASDAQ:CHRS Coherus Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Coherus Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.09 -0.80 (-4.02 %) (As of 09/21/2020 02:56 PM ET) Add Compare Share Today's Range$18.98Now: $19.09▼$19.6750-Day Range$17.41MA: $18.75▼$19.8952-Week Range$10.86Now: $19.09▼$23.91Volume22,997 shsAverage Volume1.37 million shsMarket Capitalization$1.36 billionP/E Ratio8.16Dividend YieldN/ABeta1.95 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCoherus Biosciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Coherus Biosciences has a forecasted upside of 58.1% from its current price of $18.98.Amount of Analyst CoverageCoherus Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCoherus Biosciences has received 398 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCoherus Biosciences has received 383 “underperform” votes. (Add your “underperform” vote.)Community SentimentCoherus Biosciences has received 50.96% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote “Outperform” if you believe CHRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCoherus Biosciences does not currently pay a dividend.Dividend GrowthCoherus Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,337,447.00 in company stock.Percentage Held by InsidersOnly 15.86% of the stock of Coherus Biosciences is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Coherus Biosciences are expected to decrease by -47.31% in the coming year, from $1.67 to $0.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus Biosciences is 8.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus Biosciences is 8.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.99.Price to Earnings Growth RatioCoherus Biosciences has a PEG Ratio of 5.55. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCoherus Biosciences has a P/B Ratio of 12.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS Previous Symbol CUSIPN/A CIK1512762 Webwww.coherus.com Phone650-649-3530Debt Debt-to-Equity Ratio1.88 Current Ratio5.21 Quick Ratio5.00Price-To-Earnings Trailing P/E Ratio8.16 Forward P/E Ratio11.43 P/E Growth5.55 Sales & Book Value Annual Sales$356.07 million Price / Sales3.83 Cash Flow$1.27 per share Price / Cash Flow14.98 Book Value$1.50 per share Price / Book12.73Profitability EPS (Most Recent Fiscal Year)$1.23 Net Income$89.83 million Net Margins37.11% Return on Equity139.51% Return on Assets37.87%Miscellaneous Employees232 Outstanding Shares71,470,000Market Cap$1.36 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $19.09 -0.80 (-4.02 %) (As of 09/21/2020 02:56 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CHRS News and Ratings via Email Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions How has Coherus Biosciences' stock price been impacted by COVID-19 (Coronavirus)? Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CHRS stock has increased by 20.3% and is now trading at $19.09. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Coherus Biosciences? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Coherus Biosciences. When is Coherus Biosciences' next earnings date? Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Coherus Biosciences. How were Coherus Biosciences' earnings last quarter? Coherus Biosciences Inc (NASDAQ:CHRS) issued its earnings results on Thursday, August, 6th. The biotechnology company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.44. The biotechnology company had revenue of $135.67 million for the quarter, compared to the consensus estimate of $100.33 million. Coherus Biosciences had a net margin of 37.11% and a return on equity of 139.51%. View Coherus Biosciences' earnings history. What price target have analysts set for CHRS? 8 equities research analysts have issued 12 month price targets for Coherus Biosciences' shares. Their forecasts range from $20.00 to $43.00. On average, they expect Coherus Biosciences' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 57.2% from the stock's current price. View analysts' price targets for Coherus Biosciences. Who are some of Coherus Biosciences' key competitors? Some companies that are related to Coherus Biosciences include Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Relay Therapeutics (RLAY), Ablynx (ABLYF), Halozyme Therapeutics (HALO), bluebird bio (BLUE), Immunovant (IMVT), Fate Therapeutics (FATE), Twist Bioscience (TWST), Legend Biotech (PCVX), Kodiak Sciences (KOD) and Sorrento Therapeutics (SRNE). View all competitors. What other stocks do shareholders of Coherus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), Intelsat (I), Immunomedics (IMMU), Bank of America (BAC), Idera Pharmaceuticals (IDRA), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). Who are Coherus Biosciences' key executives? Coherus Biosciences' management team includes the following people: Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)Dr. Peter K. Watler, Chief Technical Officer (Age 57)Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64) What is Coherus Biosciences' stock symbol? Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS." Who are Coherus Biosciences' major shareholders? Coherus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.30%), Goldman Sachs Group Inc. (1.81%), Bellevue Group AG (1.62%), Nuveen Asset Management LLC (1.60%), FMR LLC (1.53%) and Avidity Partners Management LP (1.43%). Company insiders that own Coherus Biosciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom and Vincent R Anicetti. View institutional ownership trends for Coherus Biosciences. Which major investors are selling Coherus Biosciences stock? CHRS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Barclays PLC, Two Sigma Advisers LP, Nuveen Asset Management LLC, Jacobs Levy Equity Management Inc., Envestnet Asset Management Inc., Platinum Investment Management Ltd., and Alps Advisors Inc.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, and Vincent R Anicetti. View insider buying and selling activity for Coherus Biosciences. Which major investors are buying Coherus Biosciences stock? CHRS stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, Redwood Investments LLC, Vanguard Group Inc., Avidity Partners Management LP, Perceptive Advisors LLC, Principal Financial Group Inc., Principal Financial Group Inc., and Thompson Siegel & Walmsley LLC. View insider buying and selling activity for Coherus Biosciences. How do I buy shares of Coherus Biosciences? Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Coherus Biosciences' stock price today? One share of CHRS stock can currently be purchased for approximately $19.09. How big of a company is Coherus Biosciences? Coherus Biosciences has a market capitalization of $1.36 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe. What is Coherus Biosciences' official website? The official website for Coherus Biosciences is www.coherus.com. How can I contact Coherus Biosciences? Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
